Skip to content
Genpharmasec logo

Genpharmasec

531592 BSE
₹1.09

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹1.09 −0.43 −28.3% 1Y
Start ₹1.52

Key Fundamentals

MicrocapCommercial ServicesServices

Price-based figures at the close · EPS basis: Consolidated · TTM

ROCE
2.68%
Debt to Equity
0.53
EPS (TTM)
₹0.00
Book Value
₹1.20
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
0.91
ROE
2.36%
Dividend Yield
0.00%
EBITDA
₹4.40 Cr
52W High
₹1.62
52W Low
₹0.75

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

46 Average

Data confidence 91/100

Category scores

Quality
33
Poor
Returns, margins, earnings quality 22% weight
Valuation
40
Weak
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
28
Poor
Solvency, leverage, coverage 9% weight
Momentum
52
Average
Trend strength, vol-adjusted 12% weight
Ownership
59
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Stock is trading at 0.92 times its book value
  • Company is expected to give good quarter
  • Debtor days have improved from 111 to 76.3 days.
  • Company's working capital requirements have reduced from 132 days to 61.1 days

Weaknesses

7
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Promoter holding is low: 30.0%
  • Company has a low return on equity of 1.74% over last 3 years.
  • Company might be capitalizing the interest cost
  • Earnings include an other income of Rs.2.83 Cr.
  • Promoter holding has decreased over last 3 years: -30.0%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish469
OscillatorsBullish162
Moving AveragesStrong Bullish307

Key readings

RSI (14)
58.45
Neutral
MACD (12,26,9)
−0.01
Bullish
SMA (50)
1.08
Bullish
SMA (200)
1.12
Bearish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
3Y+75.27%
1Y+311.76%
TTM+337.89%

Net profit

Net profit growth by window
3Y0.00%
1Y−50.00%
TTMTurned to loss

Operating cash flow

Operating cash flow growth by window
3YOutflow widened by ₹15 Cr
1YTurned negative
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
3Y+0.71 pp
1Y+0.71 pp
TTM−1.25 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2023₹26.00 Cr
Mar 2024₹30.00 Cr
Mar 2025₹34.00 Cr
Mar 2026₹140 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2023₹1.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹2.00 Cr
Mar 2026₹1.00 Cr

Quarterly Results

₹ Cr
531592 quarterly results, ₹ crore
Particulars Mar 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
6.22
7.86
6.38
10.2
5.2
6.03
8.48
14.01
12.04
32.64
39.83
55.43
49.71
Expenses
6.01
7.89
6.37
10.21
5
5.9
7.76
15.01
11.1
33.1
41.07
53.44
48.75
Operating Profit
0.21
−0.03
0.01
−0.01
0.2
0.13
0.72
−1
0.94
−0.46
−1.24
1.99
0.96
OPM %
3.38%
−0.38%
0.16%
−0.1%
3.85%
2.16%
8.49%
−7.14%
7.81%
−1.41%
−3.11%
3.59%
1.93%
Other Income
0.06
0.15
0.14
0.31
0.57
0.75
0.81
0.94
0.69
0.46
0.98
1.02
0.37
Interest
0.06
0.07
0
0.16
0.1
0.07
0.16
0.11
0.12
0.23
0.41
0.48
0.4
Depreciation
0.01
0
0.12
0.03
0.16
0.3
0.1
0.26
0.27
0.56
0.67
0.68
0.67
PBT
0.2
0.05
0.03
0.11
0.51
0.51
1.27
−0.43
1.24
−0.79
−1.34
1.85
0.26
Tax %
−420%
80%
−100%
345.45%
35.29%
−39.22%
40.16%
−37.21%
2.42%
48.1%
−37.31%
27.03%
165.38%
Net Profit
1.05
0.01
0.06
−0.27
0.33
0.7
0.76
−0.27
1.22
−1.18
−0.83
1.36
−0.17
EPS (₹)
0.02
0
0
0
0.01
0.01
0.01
0
0.02
−0.02
−0.01
0.03
0

Profit & Loss

₹ Cr
531592 profit and loss, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
26
30
34
140
178
Expenses
25
30
33
139
176
Operating Profit
0
0
0
1
1
OPM %
1%
0.1%
1.2%
0.9%
0.7%
Other Income
0
1
3
3
3
Interest
0
0
0
1
2
Depreciation
0
0
1
2
3
PBT
0
0
2
1
0
Tax %
−300%
168%
29%
42%
—
Net Profit
1
0
2
1
−1
EPS (₹)
0.02
0
0.03
0.03
0
Div. Payout %
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
531592 balance sheet, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
28
55
55
55
Reserves
−12
9
10
11
Borrowings
3
4
5
35
Other Liabilities
1
3
9
37
Total Liabilities
20
71
80
138
Fixed Assets
0
1
8
41
CWIP
0
0
0
0
Investments
1
19
20
2
Other Assets
19
51
53
95
Total Assets
20
71
80
138

Cash Flow

₹ Cr
531592 cash flow, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−3
−3
3
−18
Investing
0
−28
−4
13
Financing
3
48
−1
4
Net Cash Flow
0
17
−3
0
Free Cash Flow
−3
−3
−3
−18
CFO/OP
−1,277
−7,275
774
−1,274

Ratios

531592 financial ratios, annual
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
82
109
147
76
Inventory Days
151
133
89
40
Days Payable
21
36
101
91
Cash Conversion Cycle
211
207
135
26
Working Capital Days
199
213
123
61
ROCE %
—
2%
4%
3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Genpharmasec insights

59 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 59.68%
  • Promoters 32.06%
  • Others 8.27%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Genpharmasec

What does Genpharmasec Ltd do?
Incorporated in 1992, Generic Pharmasec Ltd deals in pharmaceutical activities /services and trades in equity shares
Where is Genpharmasec Ltd (GENPHARMA) listed?
Genpharmasec Ltd trades under code 531592 on the BSE.
Which sector does Genpharmasec Ltd belong to?
Genpharmasec Ltd is classified under the Commercial Services sector, in the Trading & Distributors industry.
What is the 52-week high and low of Genpharmasec Ltd?
Over the last 52 weeks Genpharmasec Ltd has traded between ₹0.75 and ₹1.62 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Genpharmasec Ltd?
Genpharmasec Ltd reported a return on equity of 2.36%. Its debt-to-equity ratio is 0.53.

Company Information

Incorporated in 1992, Generic Pharmasec Ltd deals in pharmaceutical activities /services and trades in equity shares

Website genpharmasec.com
CEO Mr. Sohan Chaturvedi
Employees 10
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531592.md for Genpharmasec Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Commercial Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month